Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Receives Positive CHMP Opinion for Opdivo plus Chemotherapy for First-Line Treatment of Patients with Unresectable, Advanced, Recurrent....

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Chemotherapy for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma with Tumor Cell PD-L1.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo plus Yervoy for First-line Treatment of Patients with....

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Patients with Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo as Adjuvant Treatment for Patients with Radically Resected....

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%

Bristol Myers Squibb & Co (NYSE: BMY) has received positive CHMP opinion for Opdivo (nivolumab) plus chemotherapy for first-line treatment of unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. The Committee for Medicinal Products for Human Use (CHMP) of the.

Why Bristol Myers' Shares Are Trading Higher Today

The FDA accepts Bristol Myers' (BMY) sBLA for Breyanzi under a priority review as a second-line treatment for relapsed/refractory large B-cell lymphoma. A decision is due on Jun 24, 2022.

Bristol Myers' (BMY) Breyanzi sBLA Gets FDA's Priority Review

Bristol Myers Squibb & Co (NYSE: BMY) has announced interim results from the True North open-label extension study evaluating the long-term efficacy and safety of Zeposia (ozanimod) in active ulcerative colitis (UC).  Findings show that the percentage of patients achieving clinical remission, clinical response, endoscopic improvement, and corticosteroid-free remission was maintained through Week 142.

Bristol Myers Shares Interim Data From Long-Term Study Of Zeposia In Ulcerative Colitis

I analyzed Eli Lilly and found it expensive, and decided to look at a peer.

Bristol Myers Squibb Is My Choice For A Dividend Growth Portfolio

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ECCO2022--BMS Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod)

Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--U.S. FDA Accepts for Priority Review BMS's Supplemental Biologics License Application for Breyanzi as a Second-Line Therapy...

U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma

Bristol Myers Squibb: Bull Thesis Supported By Both Strong Technical And Fundamental Signals

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Cardiomyopathy--BMS Announces Positive Topline Results from Phase 3 VALOR-HCM Trial

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy Who are Eligible for Septal Reduction Therapy

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes

Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes

Chevron

AbbVie

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial) ( BRK.B , Financial) published its fourth-quarter 13F on Monday.

Buffett Still Likes Chevron, Continues to Sell Health Care

Exelixis

Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo (nivolumab) and Cabometyx (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma. The updated results will be featured at the American Society of Clinical Oncology (ASCO) 2022 Genitourinary Cancers Symposium.

Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion

Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion

Charter Communications

Kroger

Mastercard

Marsh & McLennan

Royalty Pharma

Sirius XM Holdings Inc

Teva Pharmaceutical

Visa

Warren Buffett once again was a net seller of equities in the fourth quarter, slicing, slashing and outright exiting stakes across a series of sectors that have fallen out of his favor. But the Oracle of Omaha did pull off a few interesting buys in Q4, too.

10 Stocks Warren Buffett Is Selling

PRINCETON, N.J. & ALAMEDA, Calif.--(BUSINESS WIRE)---- $BMY #ASCO--Opdivo in Combination with CABOMETYX Demonstrates Continued Survival Benefits

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

CVS Health

General Dynamics

Lockheed Martin

Burry's Scion Asset Management swapped out four of its six US stocks last quarter, helping to boost its portfolio's value by 78%.

'Big Short' investor Michael Burry discloses new bets on Bristol-Myers Squibb and General Dynamics — and reveals he sold CVS Health and Lockheed Martin

Amgen

Sanofi

Vertex Pharmaceuticals

Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.

Will the Rally of These 5 Big Drugmakers Continue in 2022?

BASF SE

Deutsche Telekom AG

3 Companies With Safe Yield And Significant Upside

Bath and Body Works

DuPont de Nemours

PepsiCo

Twitter

There are several ways that a company can return wealth to its shareholders. Price appreciation and dividends are the two most common ways, but there are other ways a company can introduce returns to buyers.

6 Companies That Recently Announced Large Buybacks

Abbott Labs

Alnylam Pharmaceuticals

Cerner

Regeneron Pharmaceuticals

Stryker

Waters

The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2021 portfolio earlier this week.

The Vanguard Health Care Fund's Top 5 Trades

Bristol Myers Squibb BMY, -0.45% said Wednesday it has entered a $5 billion accelerated share buyback program with Morgan Stanley, Barclays Bank, Citibank and JP Morgan. The deal is part of the drug company's $15 billion share buyback program and it will have about $10.2 billion remaining in the authorization once the accelerated deal closes.

Bristol Myers Squibb announces $5 billion accelerated share buyback program

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements

Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements

Eli Lilly

Merck

Should investors be putting these pharmaceutical stocks on their watchlists?

News for Bristol-Myers Stock (BMY)